- Auteur(s) : Vasco Vieira Serrão, Andréa Martins, M João Paiva Lopes
, Dermatology Department, Hospital dos Capuchos, Alameda Santo António dos Capuchos, 1150 – 314 Lisboa, Portugal
- Mots-clés : anti-TNF-alpha, arthropatic, biologics, infliximab, pustular psoriasis
- Page(s) : 71-3
- DOI : 10.1684/ejd.2008.0314
- Année de parution : 2008
Generalized pustular psoriasis is an unstable inflammatory type of psoriasis, with widespread areas of erythema and sterile pustules, associated with fever and systemic symptoms. Infliximab is a monoclonal antibody with anti-TNFα activity, approved for use in psoriasis. We describe a male patient with a long history of stable arthropathic psoriasis, hospitalized with a generalized pustular psoriasis and acute exacerbation of articular complaints. The disease was resistant to multiple therapies (acitretin, methotrexate and corticosteroids), so the patient was started on infliximab, with a very rapid response of both cutaneous and articular symptoms. He had complete clearing of lesions at week 12, and marked improvement of the articular symptoms. No recurrence occurred at 8 months of follow-up with infliximab every 8 weeks. Infliximab had an extremely rapid therapeutic action response on a recalcitrant generalized pustular psoriasis. The articular response was also excellent, with significant improvement of quality of life.